2-Butyl-N-methylanilin | 136539-70-3

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 2-Butyl-N-methylanilin
• 英文别名: 2-butyl-N-methylaniline
• CAS: 136539-70-3
• 化学式: C₁₁H₁₇N
• 分子量: 163.263
• InChiKey: YBGGKFXBLBALPM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  12
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  12
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  1-碘丁烷 、 N-甲基苯胺 生成 N-戊基苯胺 、 2-Butyl-N-methylanilin
  参考文献：
  名称：

  Lithium-N-lithiomethyldithiocarbamate: NeueN-Alkylaminomethylanion-Äquivalente II¹Untersuchungen zur Anwendungsbreite der Methode: Sterisch gehinderte und aromatischeN-Methylamine

  摘要：

  N-锂甲基二硫代氨基甲酸锂：新的 N-烷基氨基甲基阴离子等价物 II1 方法范围的研究：研究了作为二硫代氨基甲酸锂保护的仲甲胺的甲基去质子化范围。支链 N-烷基甲胺（如环己基衍生物）可以发生去质子化反应，但 N-叔丁基甲胺则不能。对于芳香族甲胺（如 N-甲基苯胺），根据所用碱的不同，可以进行区域选择性甲基和正交去质子化反应。

  DOI：

  10.1055/s-1991-26532

文献信息

• NOVEL MOLECULES THAT SELECTIVELY INHIBIT HISTONE DEACETYLASE 6 RELATIVE TO HISTONE DEACETYLASE 1
  申请人：The Trustees of Columbia University in the City of New York

  公开号：US20140288119A1

  公开（公告）日：2014-09-25

  This invention provides a compound having the structure: wherein R 1 is H, halogen, —NR 5 R 6 , —NR 5 —C(═O)—R 6 , —NH—C(═O)—OR 7 , —OR 7 , —NO 2 , —CN, —SR 7 , —SO 2 R 7 , —CO 2 R 7 , CF 3 , —SOR 7 , —POR 7 , —C(═S)R 7 , —C(═O)—NR 5 R 6 , —CH 2 —C(═O)—NR 5 R 6 , —C(═NR 5 )R 6 , —P(═O)(OR 5 )(OR 6 ), —P(OR 5 )(OR 6 ), —C(═S)R 7 , C 1-5 alkyl, C 2-5 alkenyl, C 2-5 alkynyl, aryl, heteroaryl, or heterocyclyl, wherein R 5 , R 6 , and R 7 and are each, independently, H, C 1-5 alkyl, C 2-5 alkenyl, C 2-5 alkynyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; m is an integer from 0 to 2; R 2 and R 3 are each, independently, H, halogen, —NH 2 , —CX 3 , —C(═O)OR 8 , C(═O)R 8 , —C(═O)NR 9 R 10 , C 1-10 alkyl, C 2-10 alkenyl, C 2-10 alkynyl, heteroalkyl, aryl, heteroaryl, or heterocyclyl; wherein X is Cl, Br, or F; R 8 , R 9 and R 10 are each, independently, H, C 1-5 alkyl, C 2-5 alkenyl, C 2-5 alkynyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; Q is —Ar 1 —Z— or —Z—Ar 1 —Z—, wherein Ar 1 is aryl or heteroaryl; and each occurrence of Z is independently present or absent, and when present is —O—, —S—, —CH 2 —, —C(O)— —NH—, —NH—NH—, —NHC(═O)—, —C(═O)NH—, —NHC(═O)CH 2 NH—, —NHC(═O)CH 2 C(═O)—, —N(OH)—, —CH 2 CH 2 — or —NHC(═O)CH═CH—; and R 4 is alkyl, —OR 11 or —NH—OR 11 , wherein R 11 is H, C 1-10 alkyl, C 2-10 alkenyl, C 2-10 alkynyl, aryl, heteroaryl, or heterocyclyl, and when Q is —Ar 1 —Z—, Z is absent, Ar 1 is phenyl, R 2 and R 3 are H, n=1, and R 4 is —NHOH, then R 1 is other than carbazole, tetrahydro-β-carboline, tetrahydro-γ-carboline, —C(═O)—NR 5 R 6 and —NR 5 —C(═O)—R 6 , wherein one of R 5 or R 6 is quinoline and the other of R 5 or R 6 is H; or a pharmaceutically acceptable salt thereof.

  该发明提供了一种具有以下结构的化合物：其中，R1为H、卤素、—NR5R6、—NR5—C(═O)—R6、—NH—C(═O)—OR7、—OR7、—NO2、—CN、—SR7、—SO2R7、—CO2R7、CF3、—SOR7、—POR7、—C(═S)R7、—C(═O)—NR5R6、—CH2—C(═O)—NR5R6、—C(═NR5)R6、—P(═O)(OR5)(OR6)、—P(OR5)(OR6)、—C(═S)R7、C1-5烷基、C2-5烯基、C2-5炔基、芳基、杂芳基或杂环烷基，其中，R5、R6和R7各自独立地为H、C1-5烷基、C2-5烯基、C2-5炔基、杂基、环烷基、杂环烷基、芳基或杂芳基；m为0到2的整数；R2和R3各自独立地为H、卤素、—NH2、—CX3、—C(═O)OR8、C(═O)R8、—C(═O)NR9R10、C1-10烷基、C2-10烯基、C2-10炔基、杂基、芳基、杂芳基或杂环烷基，其中，X为Cl、Br或F；R8、R9和R10各自独立地为H、C1-5烷基、C2-5烯基、C2-5炔基、杂基、环烷基、杂环烷基、芳基或杂芳基；Q为—Ar1—Z—或—Z—Ar1—Z—，其中，Ar1为芳基或杂芳基；Z的每次出现都是独立存在或缺失的，当存在时为—O—、—S—、—CH2—、—C(O)——NH—、—NH—NH—、—NHC(═O)—、—C(═O)NH—、—NHC(═O)CH2NH—、—NHC(═O)CH2C(═O)—、—N(OH)—、—CH2CH2—或—NHC(═O)CH═CH—；R4为烷基、—OR11或—NH—OR11，其中，R11为H、C1-10烷基、C2-10烯基、C2-10炔基、芳基、杂芳基或杂环烷基，当Q为—Ar1—Z—，Z不存在，Ar1为苯基，R2和R3为H，n=1，且R4为—NHOH时，R1不是咔唑、四氢-β-咔啉、四氢-γ-咔啉、—C(═O)—NR5R6和—NR5—C(═O)—R6，其中R5或R6之一为喹啉，另一个为H；或其药学上可接受的盐。
• Novel piperidine derivative
  申请人：Ohtake Norikazu

  公开号：US20090203710A1

  公开（公告）日：2009-08-13

  Provided are a histamine-H3 receptor antagonist; and a preventive and/or a remedy for metabolic system diseases such as obesity, diabetes, hormone secretion disorder, hyperlipemia, gout, fatty liver, circulatory system diseases, for example, stenocardia, acute/congestive cardiac insufficiency, cardiac infarction, coronary arteriosclerosis, hypertension, nephropathy, sleep disorder and various diseases accompanied by sleep disorder such as idiopathic hypersomnia repetitive hypersomnia, true hypersomnia, narcolepsy, sleep periodic acromotion disorder, sleep apnea syndrome, circadian rhythm disorder, chronic fatigue syndrome, REM sleep disorder, senile insomnia, night worker sleep insanitation, idiopathic insomnia, repetitive insomnia, true insomnia, electrolyte metabolism disorder; and central and peripheral nervous system diseases such as bulimia, emotional disorder, melancholia, anxiety, epilepsy, delirium, dementia, shinzophrenia, attention deficit/hyperactivity disorder, memory disorder, Alzheimer's disease, Parkinson's disease, sleep disorder, recognition disorder, motion disorder, paresthesia, dysosmia, epilepsy, morphine resistance, narcotic dependency, alcoholic dependency. The histamine-H3 receptor antagonist comprises a piperidine derivative compound of formula (I) [wherein X 1 and X 2 independently represent a nitrogen atom or CH; Y represents a specific group; X 3 represents O s —(CH 2 ) m ; R 1 and R 2 independently resent a hydrogen atom, a halogen atom, a linear or branched lower alkyl group, a lower alkoxy group, or an acetyl group substituted with 2 or 3 fluorine atoms; s is 0 or 1; and m is an integer to make (m+s) 0 or from 1 to 4], or its pharmaceutically-acceptable salt.

  提供了一种组织胺H3受体拮抗剂和一种预防和/或治疗代谢系统疾病的药物，例如肥胖症、糖尿病、激素分泌障碍、高脂血症、痛风、脂肪肝、循环系统疾病（例如心绞痛、急性/充血性心力衰竭、心肌梗塞、冠状动脉粥样硬化、高血压、肾病、睡眠障碍以及伴随睡眠障碍的各种疾病，如特发性嗜睡、反复嗜睡、真性嗜睡、嗜睡性周期性运动障碍、睡眠呼吸暂停综合征、生物钟节律障碍、慢性疲劳综合征、REM睡眠障碍、老年性失眠、夜班工人睡眠不洁、特发性失眠、反复失眠、真性失眠、电解质代谢障碍）；以及中枢和周围神经系统疾病，如暴食症、情绪障碍、忧郁症、焦虑症、癫痫、谵妄、痴呆、精神分裂症、注意力缺陷/多动障碍、记忆障碍、阿尔茨海默病、帕金森病、睡眠障碍、认知障碍、运动障碍、感觉异常、嗅觉异常、癫痫、吗啡耐受、麻醉药依赖和酒精依赖。 组织胺H3受体拮抗剂包括式（I）的哌啶衍生物化合物（其中X1和X2独立地表示氮原子或CH；Y表示特定的基团；X3表示Os-（CH2）m；R1和R2独立地表示氢原子、卤素原子、线性或支链低碳基、低碳氧基或乙酰基，被2或3个氟原子取代；s为0或1；m是一个整数，使（m+s）为0或1到4），或其药学上可接受的盐。
• THERAPEUTIC GUANIDINES
  申请人：CAMBRIDGE NEUROSCIENCE, INC.

  公开号：EP0751767A1

  公开（公告）日：1997-01-08
• EP0751767A4
  申请人：——

  公开号：EP0751767A4

  公开（公告）日：1997-12-10
• US7834182B2
  申请人：——

  公开号：US7834182B2

  公开（公告）日：2010-11-16

表征谱图